Centre of Postgraduate Medical Education, Warsaw, Poland.
National Medical Institute of the Ministry of Interior and Administration in Warsaw, Poland, Pathomorphology Department, Warsaw, Poland.
Ginekol Pol. 2024;95(4):252-258. doi: 10.5603/gpl.96605. Epub 2023 Oct 24.
The aim of the study was to evaluate the B7-H4 expression in endometrial cancer cells and to investigate its relationship with patient prognosis and clinicopathological features of the disease.
We performed a single-center, retrospective cohort study that included endometrial cancer patients treated between 2012 and 2019. B7-H4 expression in specimens obtained from 63 patients was examined by immunohistochemical staining. The evaluation of B7H4 immunoreactivity was assessed using Immunoreactivity Scoring (IRS) system.
B7-H4 reactivity was observed in all, except one, endometrial cancer patients (98%). Staining intensity: no reaction in one case, weak in 16 (24%) patients, moderate in 25 (37%), and strong in 22 (35%). Twenty-nine (46%) patients showed B7-H4 immunoreactivity in more than 60% of cells, while, in 18 (29%) cases and 16 (25%) patients, the percentages were 30-60% and < 30% respectively. Median IRS was 2 (range 0-6). We found a significantly worse overall survival (OS) rate for patients with high versus low B7-H4 IRS (p = 0.03), however, in multivariate analysis, the difference in patient survival was close to the significance level (p = 0.052). B7-H4 expression was not related to histopathological type of the tumor, tumor grade, lymph node metastases, or the FIGO stage of the disease.
Our result suggests that B7-H4 expression might be a useful prognostic factor in endometrial cancer.
本研究旨在评估子宫内膜癌细胞中 B7-H4 的表达，并探讨其与患者预后及疾病临床病理特征的关系。
我们进行了一项单中心回顾性队列研究，纳入了 2012 年至 2019 年间治疗的子宫内膜癌患者。对 63 例患者的标本进行免疫组织化学染色，检测 B7-H4 的表达。采用免疫反应评分（IRS）系统评估 B7H4 免疫反应性。
除 1 例外，所有子宫内膜癌患者（98%）均可见 B7-H4 反应。染色强度：1 例无反应，16 例（24%）弱反应，25 例（37%）中度反应，22 例（35%）强反应。29 例（46%）患者有超过 60%的细胞呈 B7-H4 免疫反应性，而 18 例（29%）和 16 例（25%）患者的百分比分别为 30-60%和<30%。IRS 中位数为 2（范围 0-6）。我们发现 B7-H4 IRS 高与低的患者总生存（OS）率有显著差异（p=0.03），然而，在多变量分析中，患者生存的差异接近显著性水平（p=0.052）。B7-H4 表达与肿瘤的组织学类型、肿瘤分级、淋巴结转移或疾病的 FIGO 分期无关。
我们的结果表明，B7-H4 表达可能是子宫内膜癌的一个有用的预后因素。
